ライフサイエンスコーパス: person-year

1 al toilets to communal septic tanks (3-5 USD/person/year).

2 dividuals without adenomas (22.2 per 100,000 person-years).

3 in older age groups (range, 7 to 11 per 100 person-years).

4 ll sites (incidence rate 24.9 cases per 1000 person-years).

5 mes higher than in HICs (3.4 deaths per 1000 person-years).

6 peak in people 80 years or older (0.79 p/100 person-years).

7 that of controls (121.5 versus 24.6 per 1000 person-years).

8 h a CAC of zero (50%) (5.2 vs. 5.0 per 1,000 person-years).

9 n developed ovarian cancer (58 cases/100 000 person-years).

10 s were followed up over 7936 eye-years (4676 person-years).

11 rson-years) than in HICs (4.3 cases per 1000 person-years).

12 nce rate of 5.7 (95% CI = 5.5-5.8) per 1,000 person years.

13 ade, or an average incidence of 0.39 per 100 person-years.

14 deaths and 5126 nonstroke deaths in 175 084 person-years.

15 D), with a mean incidence of 0.9-1.4 per 100 person-years.

16 onfidence interval [CI]: 52.7-80.4) per 1000 person-years.

17 ssociated hospitalizations was 45.6 per 1000 person-years.

18 o STI had 5186 HIV diagnoses over 24 359 397 person-years.

19 on-years and of serious AEs was 9.88 per 100 person-years.

20 6.8% and an incidence of 0.58-2.89 per 1,000 person-years.

21 er-specific mortality rate of 11.77 per 1000 person-years.

22 12.3-14.1) to 7.1 (95% CI, 6.3-7.8) per 1000 person-years.

23 of SAH was 4.6 (95% CI 1.9 to 11.0) per 1000 person-years.

24 ndardised incidence of these events per 1000 person-years.

25 ce of AKI was 9.3 (95% CI 0.78-1.22) per 100 person-years.

26 ed for a mean of 10 years approximating 8500 person-years.

27 CI 9.03-11.60) additional deaths per 10 000 person-years.

28 fference of -2.9 (CI, -3.6 to -2.1) per 1000 person-years.

29 ver 5 years or an incidence rate of 12.1/100 person-years.

30 background) to 15.0 (Puerto Ricans) per 1000 person-years.

31 abilities and report incidence rates per 100 person-years.

32 57.5 (95% CI: 56.0, 59.0) cases per 100 000 person-years.

33 dence rate of 7.0 (95% CI, 6.9-7.1) per 1000 person-years.

34 r a median period of 7.8 y, totaling 282,855 person-years.

35 th an overall incidence of 2.5 cases per 100 person-years.

36 ients on OST ranged from 0.0 to 12.5 per 100 person-years.

37 s died, corresponding to 22 deaths per 1,000 person-years.

38 dence of RSV pneumonia was 29 cases per 1000 person-years.

39 en, 60% African American) contributed 30 007 person-years.

40 occurred: 2.3 (95% CI 0.3 to 16.6) per 1000 person-years.

41 ogic, 11 clinical) at a rate of 3.78 per 100 person-years.

42 rs and in Kavrepalanchok was 615 per 100 000 person-years.

43 ce would fall to 1.09 (0.87 to 1.29) per 100 person-years, 1.42 (1.13 to 1.71) per 100 person-years a

44 rral was estimated at 2.62 cases per 100 000 person-years (105 PY) (95% credible interval [CI], 1.53-

45 3 to 82.8 steps per minute; and 5.3 per 1000 person-years (108 deaths) for the 1037 individuals who t

46 56.1 to 69.2 steps per minute; 6.8 per 1000 person-years (124 deaths) for the 1074 individuals who t

47 e clusters that received RACD; 30.2 per 1000 person-years (15.0-45.5) in the clusters that received R

48 ook 4000 to 7999 steps per day; 6.9 per 1000 person-years (176 deaths) for the 1539 individuals who t

49 eighted incidence rate difference [IRD]/1000 person-years, -19.5 [95% CI, -20.4 to -18.5]).

50 ters that received RAVC versus 38.9 per 1000 person-years (20.7-57.1) in the clusters that did not re

51 18.5 to 56.0 steps per minute; 12.6 per 1000 person-years (207 deaths) for the 1153 individuals who t

52 eceived rfMDA plus RAVC versus 41.4 per 1000 person-years (21.5-61.2) in the clusters that received R

53 ers that received rfMDA versus 38.3 per 1000 person-years (23.0-53.6) in the clusters that received R

54 During follow-up (3,597,146 person-years), 25,288 women developed asthma, an inciden

55 rituximab 33 (incidence rate [IR] per 10,000 person-years = 34.4, 95% confidence interval [CI] = 23.7

56 nd nonusers, respectively (weighted IRD/1000 person-years, -4.1 [95% CI, -5.1 to -3.0]).

57 rtality by peak 30 cadence was 32.9 per 1000 person-years (406 deaths) for the 1080 individuals who t

58 ty for all-cause mortality was 76.7 per 1000 person-years (419 deaths) for the 655 individuals who to

59 less than 4000 steps per day; 21.4 per 1000 person-years (488 deaths) for the 1727 individuals who t

60 illion individuals observed over 161 935 233 person-years (49.1% males), 35 483 died by suicide (medi

61 e IR of 12.3 (95% CI, 10.4-14.7) per 100 000 person-years (5 studies including 1 079 489 person-years

62 that did not receive RAVC; and 25.0 per 1000 person-years (5.2-44.7) in the clusters that received rf

63 (observed January 2010-December 2016; total person-years 6,498,607) with linked FHS utilization and

64 Among 21 046 PLWH contributing 103 348 person-years, 67% of person-years were retained.

65 During the 17-year follow-up (1,340,423 person years), 7,614 new asthma cases occurred, giving a

66 he median 3.1-year follow-up period (302,526 person-years), 732 deaths were recorded.

67 ior, HCV incidence would drop to 0.6 per 100 person-years (76% decline).

68 00 to 11 999 steps per day; and 4.8 per 1000 person-years (82 deaths) for the 919 individuals who too

69 els, HCV incidence would drop to 0.4 per 100 person-years (85% decline from 2016).

70 ar end point events (incidence rate per 1000 person-years, 9.9 [95% CI, 8.1-11.9]) among SGLT2i initi

71 ipants who had initiated ART was 1.9 per 100 person-years (95% CI 0.9-3.9).

72 f locally acquired malaria was 30.8 per 1000 person-years (95% CI 12.8-48.7) in the clusters that rec

73 p, the incidence of reinfection was 1.22/100 person-years (95% CI, 0.25-3.57).

74 for a reinfection incidence of 0.81 per 100 person-years (95% CI, 0.34-1.94).

75 Recurrence rate was 10.96/1000 person-years (95% CI, 10.18-11.79) with 10-year recurren

76 nterval [CI], 1754-1789) and 303 per 100 000 person-years (95% CI, 295-310), respectively, between 20

77 observed incidence of SSTI was 78.0 per 1000 person-years (95% confidence interval 72.9-83.4) and dec

78 severe sepsis in adults was 1772 per 100 000 person-years (95% confidence interval [CI], 1754-1789) a

79 HZ incidence rate was 9.92/1000 person-years (95% confidence interval [CI], 9.82-10.01).

80 nce rate of 0.74 cases per 1000 HIV-infected person-years (95% confidence interval, 0.43-1.05).

81 esophagus (absolute difference 18.3 per 1000 person-years [95% CI 14.8-21.8]; rate ratio adjusted for

82 re revealed by CTA in 103 patients (17.2/100 person-years [95% CI, 13.9-20.5]).

83 o 5.85; rate difference, 56.4 cases per 1000 person-years; 95% CI, 38.0 to 66.8; P<.001), but the FEV

84 o 17.27; rate difference, 8.6 cases per 1000 person-years; 95% CI, 7.1 to 9.2; P < .001) but no signi

85 h celiac disease (9.7 vs 8.6 deaths per 1000 person-years; absolute difference, 1.2 per 1000 person-y

86 ed AF (incidence rate 136.4 vs 21.6 per 1000 person-years; absolute RD at 5 years, 39.3%; 95% CI, 33.

87 ve AF (incidence rate, 42.5 vs 25.0 per 1000 person-years; absolute RD at 5 years, 6.2%; 95% CI, 2.2%

88 eath (incidence rate, 133.2 vs 86.8 per 1000 person-years; absolute RD at 5 years, 9.4%; 95% CI, 4.9%

89 r TIA (incidence rate, 18.9 vs 10.0 per 1000 person-years; absolute risk difference [RD] at 5 years,

90 )plastics) released were between 8 and 877 g/person/year across all investigated WWTPs.

91 sease in the comparison group (10 per 10 000 person-years), adjusted results showed no evidence of an

92 etectable CAC (20.1 vs. 5.0 events per 1,000 person-years; adjusted hazard ratio [HR]: 2.35; 95% conf

93 d detectable hs-cTnT (15.4 vs. 5.2 per 1,000 person-years; adjusted HR: 1.47; 95% CI: 1.21 to 1.77; p

94 nce increased from 0.0 (95% CI, 0.0-2.9)/100 person-years after ART in Fiebig I to 15.9 (7.6-29.2) in

95 hat of controls (384.8 versus 180.0 per 1000 person-years after CKD diagnostic date, and 109.3 versus

96 graphic subgroups (e.g., CVD rates per 1,000 person-years: age 18 to 24 years, 0.64; age 25 to 30 yea

97 7), and 6.2 (95% CI, 5.4-7.2) deaths per 100 person-year among patients treated with DAA, IFN, and an

98 standardized CVD mortality rate was 2.7/1000 person-years among both men and women with HIV.

99 and 2 to 3 (aortic dissections) per 100 000 person-years among controls.

100 varian cancer incidence was 61 cases/100 000 person-years among ever users and 55 cases/100 000 perso

101 person-years compared with 20.1 per 100 000 person-years among individuals not diagnosed with a neur

102 among women and 0.79 (0.63 to 0.94) per 100 person-years among men.

103 -years among ever users and 55 cases/100 000 person-years among never users (estimated risk differenc

104 deaths, with 78.7 and 98.2 total deaths/1000 person-years among statin users and nonusers, respective

105 3 379 events, with 66.3 and 70.4 events/1000 person-years among statin users and nonusers, respective

106 00 person-years, 1.42 (1.13 to 1.71) per 100 person-years among women and 0.79 (0.63 to 0.94) per 100

107 ng pregnancy was 42.9 (95% CI 32.4-57.0/1000 person-years) among women for whom the mesenteric defect

108 9.6 (95% CI: 554.2, 605.0) cases per 100 000 person-years, an annual increase of 3.1% (95% CI: 2.5, 3

109 ng-cancer mortality was 2.50 deaths per 1000 person-years and 3.30 deaths per 1000 person-years, resp

110 l all-cause mortality rate of 25.56 per 1000 person-years and a liver-specific mortality rate of 11.7

111 d incidence in Kathmandu was 484 per 100 000 person-years and in Kavrepalanchok was 615 per 100 000 p

112 ted incidence rates (IRs) of GWs per 100 000 person-years and IR ratios (IRRs) with corresponding 95%

113 The incidence rate of AEs was 42.65 per 100 person-years and of serious AEs was 9.88 per 100 person-

114 erval, 3.09-7.27] vs 0.87 [.42-1.83] per 100 person-years) and dyslipidemia (8.16 [5.42-12.27] vs 3.9

115 re double those in MICs (6.9 deaths per 1000 person-years) and four times higher than in HICs (3.4 de

116 urred more often in LICs (7.1 cases per 1000 person-years) and in MICs (6.8 cases per 1000 person-yea

117 nset HF diagnoses (1.26 versus 2.25 per 1000 person-years) and of hospitalizations for worsening HF (

118 elevant depressive symptom events; 12.9/1000 person-years) and the placebo group (625 depression or c

119 rs), lowest in adults aged 40-49 (0.35 p/100 person-years), and increased from middle age to a second

120 ed to CNV fastest (at a rate of 15.2 per 100 person-years), and those with a diagnosis of GA in the f

121 SD/person/year), onsite sanitation (2-14 USD/person/year), and mini-sewers connecting several toilets

122 ease-specific mortality rate is 10.61/10,000-person years, and the standardized mortality ratio (SMR)

123 9-30.9), and 18.4 (95% CI, 8.8-33.8) per 100 person-years, and 32.1 (95% CI, 20.1-48.5), 11.8 (95% CI

124 RSV illness was estimated at 536.8 per 1000 person-years, and 86% (131/153) of RSV illness episodes

125 h 2018 by an estimated 1.1 cases per 100 000 person-years annually (95% confidence interval [CI], 1.0

126 BV (Nugent 7-10) incidence was 10.18 per person-year at risk in the control group, and lower in t

127 diovascular events from 1.37 to 6.55 per 100 person-years at 2 years (adjusted hazard ratio, 4.8 [95%

128 umulative leprosy incidence was 17.4/100,000 person-years at risk (95% CI: 17.1, 17.7) and markedly h

129 dian of 11.2 years of follow-up (3.8 million person-years at risk), 2168 women developed ovarian canc

130 (CI): 22.2, 23.3, compared with 14.3/100,000 person-years at risk, 95% CI: 14.0, 14.7).

131 y" (low-burden) municipalities (22.8/100,000 person-years at risk, 95% confidence interval (CI): 22.2

132 gnostic date, and 109.3 versus 47.4 per 1000 person-years before CKD onset in those developing CKD af

133 ce to 0.73 infections (0.55 to 0.92) per 100 person-years by 2030 and 0.46 (0.33 to 0.59) per 100 per

134 ears by 2030 and 0.46 (0.33 to 0.59) per 100 person-years by 2050.

135 c control (incidence of 1 infection per 1000 person-years) by 2030.

136 rate difference of 9.0 fewer events per 1000 person-years (CI, 6.9 to 11.1).

137 ; rate difference, 1.4 fewer events per 1000 person-years [CI, 0.0 to 2.7]).

138 valent to a suicide rate of 44.0 per 100 000 person-years compared with 20.1 per 100 000 person-years

139 ng or intracranial hemorrhage (12.9 per 1000 person-years) compared with those prescribed rivaroxaban

140 t, 639 patients died from CRC (0.55 per 1000 person-years), compared with 4451 reference individuals

141 w eye progressed to GA fastest (11.2 per 100 person-years), compared with the rates per 100 person-ye

142 those prescribed rivaroxaban (21.9 per 1000 person-years), corresponding to an HR of 0.58 (CI, 0.52

143 age-standardized recurrent MI rates per 1000 person-years decreased from 89.2 to 72.3 in women and fr

144 bjects, 47,334 had incident AF (5.5 per 1000 person-years) during a 5-year mean follow-up period.

145 d 130 512 children were followed for 429 538 person-years, during which 1299 prevalent and 999 incide

146 ) and abdominal wall procedures (0.6 per 100 person-years EVR versus 1.5 per 100 person-years open; P

147 436 ESLD events; crude incidence rates/1000 person-years follow-up were 6.4 (95% confidence interval

148 h (total financial requirements of 16-24 USD/person/year), followed by container-based sanitation (10

149 n-years for 70 to <100 mg/dl, and 94.0/1,000 person-years for >=100 mg/dl.

150 rs for the LDL-C <70 mg/dl group, 60.3/1,000 person-years for 70 to <100 mg/dl, and 94.0/1,000 person

151 stroke or systemic embolism was 6.6 per 1000 person-years for adults prescribed apixaban compared wit

152 e absolute event rates approached 1 per 1000 person-years for first-degree relatives versus 11 to 13

153 , the mortality rate was 19.0 deaths per 100 person-years for the intervention group versus 21.6 deat

154 tes of cardiovascular events were 55.2/1,000 person-years for the LDL-C <70 mg/dl group, 60.3/1,000 p

155 escribed apixaban compared with 8.0 per 1000 person-years for those prescribed rivaroxaban (hazard ra

156 age-standardized ASCVD event rate per 1,000 person-years for those with a history of 1, 2, and 3 con

157 y procedure, and 53.2 (95% CI 38.9-72.8/1000 person-years) for women in whom they had been left open.

158 trol (1,174 and 1,187 versus 989 per 100,000 person-years) had prostate disorder.

159 elevant depressive symptom events; 13.3/1000 person-years) (hazard ratio, 0.97 [95% CI, 0.87 to 1.09]

160 son-years; absolute difference, 1.2 per 1000 person-years; hazard ratio [HR], 1.21 [95% CI, 1.17-1.25

161 group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69; 95% confidence interva

162 group (incidence, 1.5 vs. 2.1 events per 100 person-years; hazard ratio, 0.72; 95% CI, 0.57 to 0.92;

163 patients, respectively (4.3 and 2.8 per 100 person-years; hazard ratio, 1.50; 95% CI, 0.95 to 2.37;

164 group (incidence, 0.7 vs. 0.5 events per 100 person-years; hazard ratio, 1.51; 95% CI, 0.99 to 2.31).

165 ence), hs-cTnT >= LoD/CAC = 0: 6.8 per 1,000 person-years (HR: 1.59; 95% CI: 1.17 to 2.16; p = 0.003)

166 .003), hs-cTnT < LoD/CAC > 0: 11.1 per 1,000 person-years (HR: 2.74; 95% CI: 1.96 to 3.83; p < 0.0000

167 , and hs-cTnT >= LoD/CAC > 0: 22.6 per 1,000 person-years (HR: 3.50; 95% CI: 2.60 to 4.70; p < 0.0000

168 th 4451 reference individuals (0.38 per 1000 person-years; HR 1.59, 95% CI 1.46-1.72) during the same

169 cardiovascular disease (3.5 vs 3.4 per 1000 person-years; HR, 1.08 [95% CI, 1.02-1.13]), cancer (2.7

170 oke (incidence rate, 5.6 versus 3.2 per 1000 person-years; HR, 1.19 [95% CI, 0.82-1.72]).

171 and respiratory disease (0.6 vs 0.5 per 1000 person-years; HR, 1.21 [95% CI, 1.08-1.37]).

172 CI, 1.02-1.13]), cancer (2.7 vs 2.2 per 1000 person-years; HR, 1.29 [95% CI, 1.22-1.36]), and respira

173 ing the years 2010-2017 (7.5 vs 5.5 per 1000 person-years; HR, 1.35 [95% CI, 1.21-1.51]).

174 ion (incidence rate, 3.9 versus 1.8 per 1000 person-years; HR, 1.37 [95% CI, 0.88-2.13]) and ischemic

175 range of 18 to 39 years (1.9 vs 1.1 per 1000 person-years; HR, 1.69 [95% CI, 1.47-1.94]; P values for

176 person-years (5 studies including 1 079 489 person-years; I(2) = 0%).

177 ients using DPP4 inhibitors and 4 per 10 000 person-years in 10 684 using GLP-1 mimetics, 6861 of who

178 ence in our model increased from 0.7 per 100 person-years in 2000 to 2.5 per 100 person-years in 2016

179 ) and declined from 96.0 infections per 1000 person-years in 2009 to 56.5 infections per 1000 person-

180 ncidence decreased 25% annually from 1.7/100 person-years in 2012 to 0.5/100 person-years in 2019 (in

181 creased from 8.4 in 2000 to 20.2 per 100,000 person-years in 2013.

182 on-years in 2009 to 56.5 infections per 1000 person-years in 2014 (P < .001).

183 per 100 person-years in 2000 to 2.5 per 100 person-years in 2016 and had the same trajectory as prev

184 from 1.7/100 person-years in 2012 to 0.5/100 person-years in 2019 (incidence rate ratio 0.75; CI:0.68

185 ence of Parkinson's disease was 8 per 10 000 person-years in 21 175 patients using glitazones, 5 per

186 175 patients using glitazones, 5 per 10 000 person-years in 36 897 patients using DPP4 inhibitors an

187 phageal cancer and 0.09 ONJ events per 1,000 person-years in the alendronate cohort and 6.62, 7.36, 0

188 s in the intervention group and 14.7 per 100 person-years in the control group (hazard ratio 0.98, 95

189 ntervention group versus 21.6 deaths per 100 person-years in the control group (unadjusted hazard rat

190 the screening group and 4.91 cases per 1000 person-years in the control group; lung-cancer mortality

191 -25.7), and 28.2 (95% CI, 13.5-51.9) per 100 person-years in the early, late integrated, and sequenti

192 nce of unintended pregnancy was 15.5 per 100 person-years in the intervention group and 14.7 per 100

193 cidence of severe morbidity was 11.1 per 100 person-years in the maraviroc group and 11.2 per 100 per

194 ears in the maraviroc group and 11.2 per 100 person-years in the placebo group (hazard ratio, 0.97 [9

195 us cardiovascular events, with rates per 100 person-years in the placebo, 50 mg, 150 mg, and 300 mg c

196 dence of lung cancer was 5.58 cases per 1000 person-years in the screening group and 4.91 cases per 1

197 The ADHD incidence rate was 3.41 per 1,000 person-years in the Tdap-vaccinated women and 3.93 per 1

198 the Tdap-vaccinated women and 3.93 per 1,000 person-years in the unvaccinated (hazard ratio = 1.01, 9

199 ded 2 or higher was 36.1 versus 41.5 per 100 person-years (incidence rate ratio, 0.87 [CI, 0.65 to 1.

200 The age-adjusted incidence per 1000 person-years increased with the number of SDH for both f

201 The rate of the primary outcome (per 100 person-years) increased with HF duration: 10.2 (95% CI,

202 in infants younger than 1 year (15.0 per 100 person-years), lowest in adults aged 40-49 (0.35 p/100 p

203 voiding 1.75 million deaths or 20.5 trillion person years of life lost would be valued at $10.2 to $1

204 Events per person-year of follow-up among participants randomized t

205 79 participants aged 14 to 48 years (262,535 person-years of education data from 1979 to 2014).

206 88 818 SPC deaths occurred during 11 197 890 person-years of follow-up (mean, 7.3 years).

207 y higher among frail participants: 25.7/1000 person-years of follow-up (PYFU) (95% confidence interva

208 s 73.9%).There were 619 events during 27,159 person-years of follow-up (PYFU): 540 (incidence rate [I

209 ractice Research Datalink, with 66.2 million person-years of follow-up from 2002 to 2017.

210 During 94,311 person-years of follow-up in 2007-2017, 7,779 primary ev

211 e intervention group and 28.6 events per 100 person-years of follow-up in the control group (hazard r

212 The corresponding incidence rates per 10 000 person-years of follow-up in the highest vs the lowest q

213 reported fall injury was 25.6 events per 100 person-years of follow-up in the intervention group and

214 During 3,354,957 person-years of follow-up, 20,831 women and 12,397 men d

215 After 440 person-years of follow-up, 44% of YBMSM initiated PrEP t

216 In 47.5 million person-years of follow-up, 49,955 (2.3%) women were diag

217 During 3,316,633 person-years of follow-up, 6576 cases of incident kidney

218 Over 246 person-years of follow-up, the incidence of reinfection

219 During 5,291,518 person-years of follow-up, we documented 15,837 incident

220 During 355 918 person-years of follow-up, we documented 4536 deaths fro

221 t CRC cases occurred over 16 y and 6,464,527 person-years of follow-up.

222 ted, or immune-based therapies) with 148,138 person-years of follow-up.

223 om March 2002 to September 2014, with 64,648 person-years of follow-up.

224 ses of CD and 428 cases of UC over 4,949,938 person-years of follow-up.

225 primary-care sites annually providing 13,801 person-years of follow-up; 50-60% received an HCV test a

226 total of 75 558 persons contributed 166 723 person-years of follow-up; 519 seroconverted.

227 onic health data, covering about 700 million person-years of longitudinal observation time nationwide

228 The incidence rate per 1,000 person-years of new-onset, admission-required diagnosis

229 s exposed to OAT, HCV incidence was 16.5/100 person-years of observation (PYO) (95% CI, 13.1-20.7) in

230 st antibody test, HCV incidence was 2.25/100 person-years of observation (PYO).

231 rson-years), compared with the rates per 100 person-years of progression to CNV (3.2-11.9) or GA (2.0

232 wed by container-based sanitation (10-17 USD/person/year), onsite sanitation (2-14 USD/person/year),

233 per 100 person-years EVR versus 1.5 per 100 person-years open; P<0.001).

234 verall, the mortality rate was 5.8 per 1,000 person-years (or 831 deaths per 100,000 live births) in

235 ry outcome was the rate of fractures per 100 person-years over 18 months.

236 -88.3) to 112.0 (95% CI 111.5-112.6) per 100 person-years over 2009 to 2018.

237 CI 3.7-3.9) to 5.0 (95% CI 4.9-5.1) per 100 person-years over the same period.

238 (64.0 exposed vs. 96.2 unexposed per 100,000 person-years, P < 0.001).

239 group, and lower in the metronidazole (1.41/person-year; p = 0.004), Ecologic Femi+ (3.58/person-yea

240 erson-year; p = 0.004), Ecologic Femi+ (3.58/person-year; p = 0.043), and Gynophilus LP groups (5.36/

241 ; p = 0.043), and Gynophilus LP groups (5.36/person-year; p = 0.220).

242 opolitan areas (0.99 versus 0.53 per 100 000 person-years; P<0.001).

243 2020 versus 2019 (1.04 versus 0.93 per 1000 person-years; P=0.02).

244 r 2020 and 2019 (1.83 versus 1.78 per 10 000 person-years; P=0.19), while hospitalizations for worsen

245 The rate of the primary outcome (per 100 person-years, placebo arm) in each age group was 13.6 (9

246 overall hospitalization rate of 35.0 per 100 person-years (PY) [95% CI: 34.3 to 35.6] and 11.1 per 10

247 CC remained stable between 1.00 and 1.23/100 person-years (PY) and 1.5 to 2.3/100 PY in patients with

248 uctive disease (by CAC scores: 6.2 per 1,000 person-years (PY) for CAC = 0 to 42.3 per 1,000 PY for C

249 d drug-free remission (incidence rate = 0.28/person-year [PY], 95% confidence interval [CI] 0.22-0.35

250 16 presidential election (573.14 per 100,000 person-years [PY]) compared to the rate in the window pr

251 LNJSA has higher incidence (13 vs 8/100 000 person-years [PY]), occurs in older, more comorbid patie

252 Mortality rate was 6.8/100 person-years (PYs) (95% CI 5.2-9.2) and TB incidence rat

253 er COPD incidence (9.8 vs 1.2 cases per 1000 person-years; rate ratio [RR], 8.12; 95% CI, 3.81 to 17.

254 rates: hs-cTnT < LoD/CAC = 0: 2.8 per 1,000 person-years (reference), hs-cTnT >= LoD/CAC = 0: 6.8 pe

255 o are waitlisted in a center relative to the person-years referred for evaluation to a program.

256 isk difference, -6.1 incident cases per 1000 person-years; relative risk, 0.55 [0.37-0.83]), or P2Y12

257 isk difference, -4.6 incident cases per 1000 person-years; relative risk, 0.61 [0.45-0.83]), and shor

258 isk difference, -3.8 incident cases per 1000 person-years; relative risk, 0.68 [95% CI, 0.54-0.87]),

259 isk difference, -3.7 incident cases per 1000 person-years; relative risk, 0.69 [0.51-0.95]).

260 The cumulative medication-free, person-year remission incidence within 5 years was 32.7%

261 iate treatment were 3592 and 811 per 100 000 person-years, respectively (P < .001).

262 871.1 [95% CI: 852.3, 890.6] cases per 1,000 person-years, respectively) and peaked in July each year

263 estimates were 12.0/11.1% and 40/29 per 100 person-years, respectively, in the base case scenario.

264 , 7.36, 0.69, 0.22 and 0.06 events per 1,000 person-years, respectively, in the raloxifene cohort.

265 3-23.0) and 10.6 (95% CI: 10.3-10.8) per 100 person-years, respectively.

266 r 1000 person-years and 3.30 deaths per 1000 person-years, respectively.

267 ession to GA or CNV were 2.0 and 3.2 per 100 person-years, respectively.

268 ) and 107.0 (95% CI, 46.2-202.0) per 100 000 person-years, respectively.

269 art abnormalities were 3.52 and 5.64 per 100 person-years, respectively.

270 , with an incidence of 2.95 and 2.88 per 100 person-years, respectively.

271 TAVR was 2.59, 0.71, and 0.40 events per 100 person-years, respectively.

272 group (incidence rates, 9.8 and 7.2 per 100 person-years, respectively; hazard ratio with rivaroxaba

273 d treatment (1951, 290, and 31 cases/100 000 person-years, respectively; P < .001).

274 ighest quartile (80.6 vs 24.2 cases per 1000 person-years; RR, 3.33; 95% CI, 1.89 to 5.85; rate diffe

275 p time was 5.0 years, and the proportions of person-years spent at each level of glucocorticoid daily

276 68 weeks (IQR: 35-127), resulting in 12,325 person-years spent with a viral load above 1,000 copies/

277 erson-years) and in MICs (6.8 cases per 1000 person-years) than in HICs (4.3 cases per 1000 person-ye

278 ibed an SGLT2 inhibitor (4.9 events per 1000 person-years) than those prescribed a GLP1 agonist (7.8

279 .16 [5.42-12.27] vs 3.99 [2.67-5.95] per 100 person-years) than those without NAFLD.

280 idence, 190.4 (95% CI: 114.8-315.8) per 1000 person-years, than nonoverweight recipients, 56.1 (95% C

281 th newer rather than injectable DMTs for 3.7 person-years to prevent 1 relapse.

282 nomas removed at screening (46.5 per 100,000 person-years) vs 309 in individuals without adenomas (22

283 Overall, the hospitalization rate per 100 person-years was 34.3 (95% confidence interval [CI], 32.

284 could be made had incidence >200 per 100 000 person-years, we observed spatial heterogeneity with up

285 plasia) at baseline, incidence rates per 100 person-years were 1.09 (95% CI, 0.85-1.33) for low-grade

286 Diabetes incidence rates per 1000 person-years were 20.6 (95% confidence interval [CI] 19.

287 Age-standardized rates of MI per 1,000 person-years were 4.5 in women and 5.7 in men without CH

288 Rates per 1000 person-years were 53.7 (95% confidence interval [CI], 50

289 sex-standardized incidence rates per 100 000 person-years were calculated by using direct adjustment

290 WH contributing 103 348 person-years, 67% of person-years were retained.

291 The 6997 included patients (19 980 person-years) were 81% cisgender men and 40% white.

292 ortality rates in LICs (13.3 deaths per 1000 person-years) were double those in MICs (6.9 deaths per

293 HIV rates diagnosis (per 100 000 person-years) were higher for women after syphilis (177.

294 for worsening HF (0.63 versus 0.99 per 1000 person-years) were significantly lower in 2020 versus 20

295 to obesity to 2.57 additional cases per 1000 person-years when added to diabetes.

296 a ranged from 1.01 additional cases per 1000 person-years when added to obesity to 2.57 additional ca

297 d from 0.91 to 1.48 per 100 000 age-specific person-years, which was the lowest in 2013 to 2015 compa

298 e each year, equating to approximately 200 g/person/year, which represents 0.13% of total plastics us

299 escribed a GLP1 agonist (7.8 events per 1000 person-years), with an HR of 0.64 (95% CI, 0.57 to 0.72)

300 equency was in children <5 years (18 per 100 person-years), with little variation in older age groups